Capital International Investors reports 1.2% CRISPR (CRSP) stake in 13G/A

Rhea-AI Filing Summary

Capital International Investors filed an amended Schedule 13G reporting its beneficial ownership of common stock of CRISPR Therapeutics AG. The firm is deemed to beneficially own 1,186,794 shares, representing 1.2% of the issuer’s 95,300,233 shares believed to be outstanding.

Capital International Investors reports sole voting and sole dispositive power over all reported shares and no shared power. The filer also certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of CRISPR Therapeutics AG.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

CRISPR Therapeutics AG

(Name of Issuer)

Common Stock

(Title of Class of Securities)

H17182108

(CUSIP Number)

01/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. H17182108

1

Names of Reporting Persons

Capital International Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,186,794.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,186,794.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,186,794.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CRISPR Therapeutics AG
(b)	Address of issuer's principal executive offices: BAARERSTRASSE 14, ZUG, ZG 6300, Switzerland
Item 2.
(a)	Name of person filing: Capital International Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: H17182108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,186,794 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 1,186,794 shares or 1.2% of the 95,300,233 shares believed to be outstanding.
(b)	Percent of class: 1.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,186,794
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,186,794
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital International Investors

Signature:	Jae Won Chung
Name/Title:	Vice President and Senior Counsel II, Capital Research and Management Company
Date:	02/05/2026

FAQ

What stake does Capital International Investors report in CRISPR Therapeutics (CRSP)?

Capital International Investors reports beneficial ownership of 1,186,794 shares of CRISPR Therapeutics common stock, representing 1.2% of the company’s 95,300,233 shares believed to be outstanding, according to this amended Schedule 13G filing.

Does Capital International Investors control voting for its CRISPR Therapeutics (CRSP) shares?

Yes. The filing states Capital International Investors has sole voting power over 1,186,794 CRISPR Therapeutics shares and no shared voting power, meaning it alone decides how these reported shares are voted in shareholder matters.

Is Capital International Investors’ CRISPR (CRSP) ownership above or below 5% of the company?

Capital International Investors reports owning 1.2% of CRISPR Therapeutics’ common stock, which is 5 percent or less of the class. The Schedule 13G explicitly notes ownership of 5 percent or less of the outstanding shares.

Why did Capital International Investors file this amended Schedule 13G for CRISPR (CRSP)?

The amended Schedule 13G reflects Capital International Investors’ updated beneficial ownership information as of the 01/30/2026 event date. Such amendments are required when ownership changes trigger reporting thresholds or classifications under SEC rules.

Is Capital International Investors seeking control of CRISPR Therapeutics (CRSP)?

No. The filer certifies the CRISPR Therapeutics shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, nor in connection with any control-related transaction.

Who signed the CRISPR Therapeutics (CRSP) Schedule 13G/A on behalf of Capital International Investors?

The filing is signed by Jae Won Chung, identified as Vice President and Senior Counsel II of Capital Research and Management Company, on 02/05/2026, certifying the truth and completeness of the ownership information reported.